Metabolic & GLP-1/GIP Agonists
Semaglutide
Also known as: Ozempic Wegovy Rybelsus
Mechanism & research context
Long-acting GLP-1 receptor agonist studied extensively in type 2 diabetes and chronic weight management.
FDA-approved indication: Type 2 diabetes (Ozempic, Rybelsus); chronic weight management (Wegovy).
Safety flags
0 flagsNo curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.
Research papers
16 recordsCitation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.
-
· 2026
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping
-
· 2026
Semaglutide is Associated with Improved Breast Cancer Survival, Lower Metastatic Burden, and a Dose–Survival Relationship Uncoupled from Weight-Loss Magnitude
-
· 2026
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss
-
· 2026 Open access
Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis.
-
· 2026
Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study.
-
· 2026 Open access
Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly.
-
· 2026
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
-
· 2026
Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.
-
· 2026
Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.
-
· 2026
Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial.
-
· 2026
Semaglutide for treatment of intractable diarrhea of different etiologies: a case series of 30 patients.
-
· 2026
Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study.
-
· 2026
Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program.
-
· 2026
Assessment of Carbon Emission Impact of Semaglutide in Patients with Type 2 Diabetes in the United Kingdom using an Innovative Modelling Approach.
-
· 2006 Open access
Semaglutide
-
Review · PubMed (NCBI) Live search link
PubMed literature search: Semaglutide
Run importer to populate live PubMed records. This placeholder links to a live search.
Clinical trials
21 records-
Live search Live search
Live ClinicalTrials.gov search: Semaglutide
Condition: See live results
Open on ClinicalTrials.gov ↗ -
NCT01686945 PHASE1 COMPLETED
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes
Condition: Diabetes; Diabetes Mellitus, Type 2; Healthy
Sponsor: Novo Nordisk A/S
Open on ClinicalTrials.gov ↗ -
NCT02249871 PHASE1 COMPLETED
A Trial Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
Condition: Diabetes; Healthy
Sponsor: Novo Nordisk A/S
Open on ClinicalTrials.gov ↗ -
NCT02453711 PHASE2 COMPLETED
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
Condition: Metabolism and Nutrition Disorder; Obesity
Sponsor: Novo Nordisk A/S
Open on ClinicalTrials.gov ↗ -
NCT02863328 PHASE3 COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
Condition: Diabetes; Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Open on ClinicalTrials.gov ↗ -
NCT03136484 PHASE3 COMPLETED
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
Condition: Diabetes; Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Open on ClinicalTrials.gov ↗ -
NCT05153564 PHASE1 COMPLETED
Investigation of the Effect of Subcutaneously Co-administered Semaglutide and NNC0480-0389 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) in Healthy Postmenopausal Females
Condition: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Open on ClinicalTrials.gov ↗ -
NCT05537233 PHASE2 COMPLETED
Efficacy and Safety of Once Weekly Semaglutide in Adults With Obesity and Inadequately Controlled Type 1 Diabetes Using Hybrid Closed-Loop System.
Condition: Type 1 Diabetes; Obesity
Sponsor: Viral N. Shah
Open on ClinicalTrials.gov ↗ -
NCT05606471 PHASE4 UNKNOWN
The Anabolic Effects of GLP-1 Agonism to Prevent Lean Muscle Losses During Very-low Calorie Diets (VLCDs) for Weight Loss
Condition: Type 2 Diabetes Mellitus in Obese
Sponsor: University of Nottingham
Open on ClinicalTrials.gov ↗ -
NCT05646199 PHASE2 NOT_YET_RECRUITING
The Effect of Semaglutide Compared to Metformin in Obese Women With Polycystic Ovary Syndrome (PCOS): a Randomised Controlled Study (Semaglutide-PCOS Trial).
Condition: Polycystic Ovary Syndrome
Sponsor: University of Hull
Open on ClinicalTrials.gov ↗ -
NCT06289504 PHASE1 COMPLETED
An Open-label, One-sequence Cross-over, Single-centre Trial, Investigating the Influence of CagriSema on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Atorvastatin in Participants With Overweight or Obesity
Condition: Obesity
Sponsor: Novo Nordisk A/S
Open on ClinicalTrials.gov ↗ -
NCT06363747 PHASE2 ACTIVE_NOT_RECRUITING
The Medically Reproducing Bariatric Surgery (MRB) II Study: SEMAGLUTIDE Followed by OPTIFAST in Veterans With Type 2 Diabetes
Condition: Type 2 Diabetes; Obesity
Sponsor: Durham VA Medical Center
Open on ClinicalTrials.gov ↗ -
NCT06422624 PHASE1 NOT_YET_RECRUITING
An Open Label, Single Dose, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Semaglutide Extended-release Injectable Suspension in Normal Healthy, Adult, Human Study Participants Under Fasting Condition
Condition: Diabetes Mellitus, Type 2
Sponsor: Bostal Drug Delivery Co., Ltd
Open on ClinicalTrials.gov ↗ -
NCT06577090 PHASE2 ACTIVE_NOT_RECRUITING
A Phase 2 Study of QW Nimacimab Injection, Compared to Placebo Injection and QW Weekly Nimacimab Injection Co-administered With Semaglutide in Participants Who Are Overweight or Obese
Condition: Obesity
Sponsor: Skye Bioscience, Inc.
Open on ClinicalTrials.gov ↗ -
NCT06659718 COMPLETED
Emulation of the Effects of Oral Semaglutide on Cardiovascular Outcomes in Individuals With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease: SOUL Trial
Condition: Diabetes Mellitus, Type 2
Sponsor: Brigham and Women's Hospital
Open on ClinicalTrials.gov ↗ -
NCT06779929 ACTIVE_NOT_RECRUITING
Comparative Study of Tirzepatide vs Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Condition: Type 2 Diabetes
Sponsor: Brigham and Women's Hospital
Open on ClinicalTrials.gov ↗ -
NCT06913023 PHASE2 NOT_YET_RECRUITING
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
Condition: Kidney Transplant Recipient
Sponsor: University Health Network, Toronto
Open on ClinicalTrials.gov ↗ -
NCT07195994 NA RECRUITING
A Randomized, Single-blind, Controlled, Parallel Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes
Condition: Prediabetes / Type 2 Diabetes
Sponsor: QuickSilver Scientific
Open on ClinicalTrials.gov ↗ -
NCT07297589 PHASE3 RECRUITING
Epicardial Cardiac Fat Comparative Trial
Condition: STEMI - ST Elevation Myocardial Infarction; Epicardial Fat
Sponsor: Instituto Mexicano del Seguro Social
Open on ClinicalTrials.gov ↗ -
NCT07485062 PHASE4 NOT_YET_RECRUITING
Metabolic Optimization and Training InterVentions for Aging and Type 2 Diabetes to Enhance Cognition: the MOTIVATE Study
Condition: Type 2 Diabetes; Cognitive Decline in Older Adults
Sponsor: Western University, Canada
Open on ClinicalTrials.gov ↗ -
NCT07547878 PHASE4 NOT_YET_RECRUITING
A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD
Condition: Chronic Kidney Disease; Type 2 Diabetes
Sponsor: Baylor Research Institute
Open on ClinicalTrials.gov ↗
Doses reported in studies
0 recordsNo study-protocol dose records have been curated for Semaglutide yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.
Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.
These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Semaglutide, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.
Why this page does not list a dose for self-use
The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Semaglutide. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.
If this compound has an FDA-approved label
If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.
Questions worth bringing to a clinician
- What is the evidence for this compound in someone with my history?
- What are the realistic, regulator-reviewed alternatives?
- What would you monitor, and what would make you stop?
If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.